Biosimilars in development and approved by FDA 2019, by manufacturer
This statistic shows the number of biosimilars in development and approved by the FDA for hematology, inflammation and immunology, and oncology therapeutic areas in the U.S. as of May 2019, by manufacturer. At that moment, drug manufacturer Apobiologix (Apotex) had seven biosimilars in development for these areas.